SCHEMBL6140792

SCHEMBL6140792

O=C(O)c1ccccc1Nc1ccc(Cl)cc1Nc1ccccc1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 5/20 0.62
FABP3 P05413 4/20 0.59
FTO Q9C0B1 2/20 0.58
PBRM1 Q86U86 1/20 0.58
GRIK1 P39086 6/20 0.57
TTR P02766 2/20 0.56
AKR1C3 P42330 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
USP2 O75604 1/20 0.56
MT-CO2 P00403 1/20 0.56
PLA2G1B P04054 1/20 0.56
CYP1A2 P05177 1/20 0.56
PGR P06401 1/20 0.56
CYP3A4 P08684 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
AR P10275 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11603203 0.92 FABP4 (0.69) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL187951 0.92 GRIK1 (0.63) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL30753983 0.92 GRIK1 (0.63) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL7935 0.90 GRIK1 (0.61) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL29453054 0.90 GRIK1 (0.61) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL9621335 0.90 GRIK1 (0.61) FABP4FABP3FTOPBRM1GRIK1
Lobenzarit SCHEMBL1479150 0.90 GRIK1 (0.61) FABP4FABP3FTOPBRM1GRIK1
SCHEMBL24021599 0.89 LMNA (0.62) FABP4FABP3FTOPBRM1GRIK1
SCHEMBL16489012 0.89 EGFR (0.66) FABP4FABP3FTOPBRM1GRIK1
SCHEMBL16489008 0.86 TAS2R14 (0.64) FABP4FABP3FTOPBRM1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP claimed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO claimed
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP disclosed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142993-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 FABP4 4112/4885FABP3 3352/4885FTO 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.